Cost and financing of care for persons with HIV disease: an overview.
Hellinger, Fred J
Date of Pub
This article explores the impact of new combination drug therapies on the cost and financing of human immunodeficiency virus
(HIV) disease. Evidence indicates that the proportion of costs attributable to drugs has increased significantly since the
diffusion of new combination drug therapies, and that the proportion of costs attributable to hospital inpatient care has
decreased. The absence of timely data is the major difficulty in analyzing the impact of recent changes. Only two studies
have examined costs since the diffusion of new combination drug therapies, and there are no recent studies of the insurance
status of persons with HIV disease.
Cost of Illness : Anti-HIV Agents/administration & dosage/economics/therapeutic use : Drug Costs/statistics & numerical data
: Drug Therapy, Combination : Female : Health Care Costs/statistics & numerical data : Health Services Research : HIV Infections/drug
therapy/economics : HIV Protease Inhibitors/administration & dosage/economics/therapeutic use : Human : Male : Medicaid/statistics
& numerical data/utilization : Racial Stocks : Sex Factors : Substance-Related Disorders : United States